INDIANAPOLIS, Jan. 15, 2025 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has approved Omvoh (mirikizumab-mrkz) for the treatment of moderately to severely active Crohn's disease…Original Article
FDA Approves Lilly’s Omvoh (mirikizumab-mrkz) for Crohn’s Disease, Expanding Its Use to the Second Major Type of Inflammatory Bowel Disease
